Yungjin Pharm. Co., Ltd.

A003520

KR7003520004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-07-09 EDT			5-day change	1st Jan Change
2,215 ^KRW	+0.23%		+5.23%	+4.24%

2023	Yungjin Pharm. Co., Ltd. announced that it has received KRW 30.3 billion in funding from a group of investors	CI
2023	Yungjin Pharm. Co., Ltd. announced that it expects to receive KRW 30.3 billion in funding from a group of investors	CI

Yungjin Pharm. Co., Ltd.(KOSE:A003520) dropped from Russell Global Index

June 29, 2015 at 12:00 am

Latest news about Yungjin Pharm. Co., Ltd.

Yungjin Pharm. Co., Ltd. announced that it has received KRW 30.3 billion in funding from a group of investors	11-20	CI
Yungjin Pharm. Co., Ltd. announced that it expects to receive KRW 30.3 billion in funding from a group of investors	11-16	CI
Yungjin Pharm. Co., Ltd.(KOSE:A003520) dropped from KOSPI 200 Index	22-06-09	CI
Neurovive and Yungjin Report Positive KL1333 Phase I Clinical Study Results Paving the Way for Further Clinical Development	18-05-21	CI
Neurovive Pharmaceutical AB and Yungjin Pharm Corporation Ltd Completes the Clinical Phase I Single Ascending Dose Study of KL1333	18-04-17	CI
NeuroVive Pharmaceutical AB and Yungjin Pharm Report Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333	17-12-11	CI
LG Ro Local Housing Association completed the acquisition of land and buildings at 2034 Gyeonggidae-ro, Jinwi-myeon, Pyeongtaek-si, Gyeonggi-do, South Korea from Yungjin Pharm. Co., Ltd..	17-08-07	CI
NeuroVive Pharmaceutical AB and Yungjin Pharm Corporation Ltd Announce Clinical Phase I Study of KL1333	17-06-27	CI
Neurovive Pharmaceutical AB and Yungjin Pharm Corporation Ltd Enters into Global Licensing Agreement on Yungjin Pharm's Compound KL333	17-05-01	CI
Yungjin Pharm. Co., Ltd. completed the acquisition of KT&G Life Sciences.	17-01-12	CI
LG Ro Local Housing Association signed a contract to acquire land and buildings at 2034 Gyeonggidae-ro, Jinwi-myeon, Pyeongtaek-si, Gyeonggi-do, South Korea from Yungjin Pharm. Co., Ltd. for KRW 21.4 billion.	16-08-23	CI
Yungjin Pharm. Co., Ltd. agreed to acquire KT&G Life Sciences for KRW 87.4 billion.	16-04-06	CI
Yungjin Pharm. Co., Ltd.(KOSE:A003520) dropped from Russell Global Index	15-06-29	CI
Haitai Beverage Co., Ltd. completed the acquisition of the assets of drink business unit from Yungjin Pharm. Co., Ltd..	14-12-30	CI
Haitai Beverage Co., Ltd. agreed to acquire the assets of drink business unit from Yungjin Pharm. Co., Ltd. for KRW 7.1 billion.	13-10-16	CI
Yungjin Pharm. Co., Ltd.(KOSE:A003520) added to KOSPI 200 Index	13-08-20	CI

Chart Yungjin Pharm. Co., Ltd.

Duration

Period

More charts

Yungjin Pharma Co Ltd is a Korea-based company principally engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including antibiotics, respiratory drugs, anti-infective drugs, antipyretics, analgesics, central nervous system (CNS) drugs, gastrointestinal (GI) drugs, cardiovascular (CV) drugs, antihistamines, antifungals, antidiabetics, vitamin nutrients, antibiotic raw materials, and others. The Company also engages in the leasing of real estates.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
YUNGJIN PHARM. CO., LTD.	+4.24%	293M
ELI LILLY AND COMPANY	+60.49%	846B
NOVO NORDISK A/S	+38.56%	628B
JOHNSON & JOHNSON	-4.52%	360B
MERCK & CO., INC.	+17.47%	322B
ABBVIE INC.	+8.96%	297B
ASTRAZENECA PLC	+14.09%	240B
ROCHE HOLDING AG	+3.07%	224B
NOVARTIS AG	+17.06%	223B
AMGEN INC.	+13.14%	173B

Other Pharmaceuticals